中西医结合治疗对中晚期结直肠癌生存期影响的荟萃分析

目的:评价中药配合化疗与单纯化疗或单纯中药比较对中晚期结直肠癌患者生存率的提高作用。方法:采用Cochrane系统评价方法,计算机检索CNKI、VIP和万方;同时手检相关期刊和会议论文集,纳入有关中药配合化疗治疗结直肠癌,观察其对结直肠癌患者生存影响的随机对照临床试验,并按Jadad评价标准评价纳入研究质量,对同质的研究进行Meta分析。结果:共检索到符合纳入标准的中文文献14篇(1081例患者)。文献质量评价结果显示,1篇文献为5分,属高质量研究,其余均为低质量研究。Me-ta分析合并结果显示:与单纯化疗和单纯中药相比,中药配合化疗对结直肠癌患者0.5、1、1.5、2、3、4、5年生存率的提高明显,差异有统计学意义;单项分析结果显示:3个试验中西医结合治疗结直肠癌,其1年生存率高于单纯化疗对照组,差异有统计学意义。1个试验中西医结合治疗结直肠癌,其2、3、4、5年生存率高于单纯化疗对照组,差异有统计学意义。而其余试验均未能说明其试验用药合并化疗与单纯化疗相比,对治疗结直肠癌对其生存的延长有较好的作用。结论:中药配合化疗在延长结直肠癌患者生存与单纯化疗相比有一定的优势。但由于试验用药的不同,纳入试验研究的方法学质量偏低,并不能将某一试验中药推广到临床使用,期待同一试验用药的研究设计更合理、方法更科学、样本量更大、多中心的随机双盲对照临床试验,为中药推广到临床提供更为可靠地证据。

Meta-Analysis of Integrative Medicine on Survival Time in Patients with Advanced Colorectal Cancer

Objective. To evaluate the effect of Traditional Chinese Medicine （TCM） plus chemotherapy compared with chemotherapy or TCM in the increasing of survival of colorectal cancer patients. Methods： The published clinical double-blind, randomized controlled trials which mentioned the combined therapy of TCM plus chemotherapy to treat colorectal cancer in VIP, CNKI and Wanfan database were retrieved and analyzed by Review Manager 5. 0. Results.. Seventeen clinical trials involving1082 patients were included. The quality of one study was high, the others were low. Meta-analysis combined results showed that TCM plus chemotherapy compared chemotherapy could increase the survival rate. Meta-analysis sub-grouping results showed 3 trials compared chemotherapy could increase the one year survival rate. One trial could increase the 2,3,4 and 5 year survival rate. The other trials found no statistically significant difference between 2 groups. Conclusions： There was insufficient good quality evidence on the survival rate increasing of TCM plus chemotherapy in colorectal cancer.